Ibogaine requires the most rigorous monitoring protocol in psychedelic medicine. We do not leave safety to chance, every patient is observed around the clock with clinical-grade equipment and a structured documentation system designed from first principles.
QTc interval prolongation is the single most critical safety variable in ibogaine medicine. Ibogaine blocks hERG potassium channels, which can extend the cardiac QT interval and, in patients with pre-existing vulnerability, create conditions for life-threatening arrhythmia.
MindScape records the QTc interval every 30 minutes throughout treatment, tracking the absolute value in milliseconds, the delta from each patient's personal baseline, and the cardiac rhythm classification (normal sinus, sinus bradycardia, sinus tachycardia, PVCs, SVT, and others). Our escalation protocol triggers automatically when QTc exceeds 500ms or rises more than 60ms above baseline.
This level of cardiac surveillance is not standard practice in ibogaine facilities. At MindScape, it is non-negotiable.
Every monitoring record captures heart rate, systolic and diastolic blood pressure, peripheral oxygen saturation (SpO2), respiratory rate, body temperature, and Glasgow Coma Scale (GCS) score. a neurological readiness metric that quantifies eye, verbal, and motor response.
These readings are logged at defined phase intervals: pre-dose baseline, post-test dose, pre-flood, active phase (0 to 12 hours), recovery phase (12 to 24 hours), and extended monitoring (24 to 72 hours). No patient is discharged before vitals have been stable for the required period.
Automatic escalation flags trigger when SpO2 drops below 95%, systolic BP falls below safe thresholds, or any reading deviates outside the patient-specific range established at baseline. Every intervention is documented with type, action taken, and outcome.
Beyond physiology, we document the subjective experience using structured fields: nausea severity (0 to 10 scale), vomiting episode count, experience intensity (0 to 10), and experience phase, tracking progression from pre-onset through onset, peak visionary, peak introspective, resolution, and baseline return.
These data points, aggregated across 900+ patients, allow MindScape AI to identify which experience trajectories correlate with the best long-term outcomes and which patterns indicate a patient may need additional support during or after treatment.
Phase tracking also informs optimal timing for post-treatment interventions, integration sessions, psychological assessments, and medication adjustments are timed to the patient's actual neurobiological state, not a fixed clock.
Ibogaine dosing is not a weight-based table. It requires understanding formulation purity, individual metabolizer status, withdrawal state, and real-time patient response. MindScape captures every pharmacological variable.
MindScape administers both Total Alkaloid (TA) extract and HCl (hydrochloride) formulations, each with distinct alkaloid profiles and bioavailability characteristics. TA contains ibogaine plus noribogaine and other iboga alkaloids; HCl is isolated ibogaine at higher purity.
Every dose record logs the exact raw amount in milligrams, the batch assay percentage (the actual ibogaine concentration verified by third-party laboratory analysis), batch ID, and supplier. This allows the ibogaine equivalent in mg/kg body weight to be calculated precisely. the universal safety comparator across all published research.
Ibogaine is primarily metabolized by the CYP2D6 liver enzyme. Patients who are poor metabolizers (approximately 7 to 10% of the population) cannot efficiently convert ibogaine to its primary metabolite noribogaine, resulting in significantly higher plasma ibogaine concentrations at any given dose.
MindScape records each patient's CYP2D6 status (extensive, intermediate, poor, or ultra-rapid) and genotype. Poor metabolizers receive a 30 to 50% dose reduction as standard protocol. This single variable, unknown to most facilities, accounts for a disproportionate share of adverse events at non-clinical programs globally.
Withdrawal state at time of dosing profoundly affects both ibogaine pharmacodynamics and the treatment experience. MindScape records the Clinical Opioid Withdrawal Scale (COWS) and Objective Opioid Withdrawal Scale (OOWS) scores immediately before each dose, ensuring timing is optimized for therapeutic effect.
If vomiting occurs, exact timing (minutes post-dose) is recorded to determine how much ibogaine was absorbed before emesis. When clinically indicated, re-dose amounts are documented along with the rationale. This creates a complete pharmacokinetic picture that no anecdotal account can replicate.
Ibogaine's effects unfold over months, not days. A patient who reports minimal craving at day 7 may still relapse at month 3 without proper integration and support. MindScape measures outcomes at eight standardized timepoints. from baseline through one year post-treatment, using the same validated instruments published in the peer-reviewed literature.
Assessments are conducted by both clinicians (clinician-rated scales) and patients themselves (self-report scales), providing dual-perspective data that controls for social desirability bias and captures the full clinical picture.
Measurement Timepoints
MindScape's psychological team conducts structured assessments at every major phase of treatment, intake, pre-treatment, during treatment, post-treatment, discharge, and follow-up. Each assessment captures 12 distinct psychological dimensions, each scored on a standardized 0 to 10 scale, providing a quantitative map of the patient's inner state at every critical juncture.
Risk stratification is integrated directly into the assessment workflow. Suicidal ideation screening and self-harm risk classification (none, low, moderate, high, imminent) are evaluated at every session and automatically flag cases for escalated supervision. These assessments are not administrative checkboxes. they are active inputs into treatment decisions.
Assessment types: Intake • Pre-Treatment • During Treatment • Post-Treatment • Discharge • Follow-Up
12-Dimension Scoring System
Integrated Risk Assessment
Every assessment includes structured suicidal ideation screening and a five-level self-harm risk classification. Flagged assessments trigger immediate clinical review and protocol adjustment, automatically, not at the discretion of a single clinician.
Data is only valuable if it drives decisions. MindScape AI is not a dashboard. it is a closed-loop learning system that continuously mines our clinical dataset to identify what works, for whom, and why.
No single clinician, no matter how experienced, can hold 900 patient trajectories in mind simultaneously. MindScape AI surfaces correlations invisible to human observation. which CYP2D6 genotypes pair with which dose ranges to produce the fastest and most durable symptom resolution, which monitoring phase patterns predict a difficult recovery window, which pre-treatment indicators signal the need for protocol modification.
For each primary indication, opioid use disorder, PTSD, depression, Parkinson's, alcohol dependence. MindScape AI identifies the ibogaine equivalent mg/kg band that produces the best validated outcomes (PHQ-9, PCL-5, UPDRS, COWS at 30/90 days). Crucially, it cross-references this against formulation type, CYP2D6 status, pre-dose withdrawal score, and patient weight. The result is a recommendation that no dosing table can replicate.
By training on monitoring records where escalation was triggered, MindScape AI learns the precursor signatures, subtle QTc trends, SpO2 drift patterns, or experience phase stalling. that precede clinical events. These patterns are used to alert clinical staff before thresholds are crossed, not after. Reactive medicine is replaced with predictive medicine.
Magnesium sulfate, electrolyte replacement, antiemetics, and cardiac support agents all have complex timing relationships with ibogaine. Too early and they interfere with onset; too late and they fail to prevent the adverse event they were meant to prevent. MindScape AI identifies optimal administration phases and dosing amounts for each class of supportive medication, drawn from actual outcomes across our patient population.
Before a patient ever arrives, MindScape AI synthesizes their pre-screen data. CYP2D6 status, primary indication, substance use history, weight, medical history, prior treatments, and psychological baseline, into a personalized protocol recommendation. This is reviewed and adjusted by the supervising physician, but the starting point is evidence-based and individualized, not generic.
Every patient treated today improves treatment for patients treated tomorrow. As outcome data flows in at Day 30, Day 90, and Year 1, MindScape AI updates its models. A protocol change tested on a cohort of 40 patients with CPTSD produces statistically meaningful signal within weeks, not the years required by a traditional randomized controlled trial. This is the compounding advantage of a learning health system.
MindScape's data schema was designed from the outset to meet the requirements of peer-reviewed publication. Every field traces to published clinical literature: the Stanford/MISTIC 2024 ibogaine safety study, Noller et al. (2018) on opioid use disorder outcomes, Knuijver et al. (2022) on pharmacokinetics, and GITA clinical guidelines for ibogaine administration.
We do not collect data because it is interesting. We collect it because ibogaine deserves a path from experimental treatment to evidence-based medicine, and that path runs through rigorously documented outcomes, published in journals that the mainstream medical community reads and trusts.
MindScape is positioned to be a primary contributor to that body of evidence. Our dataset, 900+ patients, 5 years, across 20+ primary indications, with 8-timepoint longitudinal follow-up, is the largest privately held ibogaine clinical dataset in the Western hemisphere.
Every data field maps to a published clinical construct. Outcome instruments are the same validated scales used in peer-reviewed ibogaine research. COWS, PHQ-9, PCL-5, MEQ-30, UPDRS, administered at timepoints matching the ibogaine literature.
From opioid use disorder to Parkinson's disease to SSRI discontinuation syndrome, our dataset spans the full spectrum of ibogaine applications, tracked longitudinally from baseline through one year post-treatment.
Our goal is not merely to run the best ibogaine program today. It is to generate the evidence that makes ibogaine available, legally, safely, and affordably, to the millions of patients who need it tomorrow.
You deserve a treatment center that knows, not guesses, what works. Speak with our clinical team about whether ibogaine is appropriate for your situation. Every conversation is confidential, and there is no obligation.